Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a NetworkNewsAudio editorial highlighting its novel approach to treating multiple sclerosis (MS). The audio press release, titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," accompanies a previously published editorial discussing the growing need for therapies that go beyond symptom management in the global MS therapeutics market, projected to reach $38.62 billion by 2030.
The feature underscores Quantum BioPharma's lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed to target the myelin sheath directly. The goal is to prevent, stop, and potentially reverse its degradation, addressing a significant unmet need for disease-modifying treatments that can alter the course of multiple sclerosis. According to the company, Lucid-MS has shown the ability to prevent and reverse myelin degradation in preclinical models, offering hope for patients who currently lack options that target the underlying mechanism of the disease.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on the research and development of Lucid-MS. The company also invented UNBUZZD(TM), an over-the-counter product, and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty payments from sales.
The announcement is significant as it highlights a potential breakthrough in MS treatment, moving beyond symptom management to address the root cause of the disease. With the MS therapeutics market expected to grow substantially, Lucid-MS could capture a significant share if it proves successful in clinical trials. Investors and patients alike are watching closely as Quantum BioPharma advances its pipeline.
For more information, visit the company's newsroom at https://nnw.fm/QNTM and view the full press release at https://nnw.fm/eI6Gv.
